Alector, Inc. (ALEC): restructuring charge — Alector's Phase 3 latozinemab trial fails; workforce cut 49%, R&D head resigns

Alector, Inc.

Phase 3 INFRONT-3 trial of latozinemab in FTD-GRN missed clinical co-primary endpoint; biomarker endpoint met but no treatment effects seen.
Workforce reduction of ~49% (about 75 employees); restructuring charges ~$7.7M; completion expected by H1 2026.
President and Head of R&D Sara Kenkare-Mitra resigns effective Dec 22, 2025; separation includes 9 months salary and 50% bonus.
Preliminary cash, equivalents, and short-term investments ~$291.1M as of Sep 30, 2025; runway expected through 2027.

item 2.02 item 2.05 item 5.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Alector, Inc. announced a restructuring with charges of approximately $7.7 million affecting across the organization (approximately 75 employees).

Type: restructuring
Charge: approximately $7.7 million
Affected area: across the organization
Headcount: approximately 75 employees

Exact text from the filing

The Company initiated a reduction in force impacting approximately 75 employees across the organization. Total incremental restructuring charges associated with the reduction in force are expected to be approximately $7.7 million.

View on SEC.gov

6 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Alector, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-245102

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.